Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Its primary program centers on bezuclastinib, a selective kinase inhibitor in clinical development. The company conducts clinical trials through third-party organizations and relies on external manufacturers for API and drug product supply. Cogent has incurred net losses since inception and does not yet have any approved commercial products.
Q2 FY2026 — expected 2026-09-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-17 | 2025-12-31 | 0001193125-26-053334 | EDGAR | 79K words |
| 2025-02-25 | 2024-12-31 | 0000950170-25-026115 | EDGAR | 77K words |
| 2024-02-26 | 2023-12-31 | 0000950170-24-019770 | EDGAR | 78K words |
| 2023-03-14 | 2022-12-31 | 0000950170-23-007729 | EDGAR | — |
| 2022-03-15 | 2021-12-31 | 0001564590-22-010238 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001564590-21-013325 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001564590-20-013188 | EDGAR | — |
| 2019-03-28 | 2018-12-31 | 0001193125-19-089299 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-10 | 2026-06-30 | 0001193125-26-342393 | EDGAR | 23K words |
| 2025-11-07 | 2025-09-30 | 0001193125-25-272334 | EDGAR | 27K words |
| 2025-08-05 | 2025-06-30 | 0000950170-25-102440 | EDGAR | 26K words |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064005 | EDGAR | 21K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124712 | EDGAR | 23K words |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091229 | EDGAR | 22K words |
| 2024-05-07 | 2024-03-31 | 0000950170-24-053977 | EDGAR | 20K words |
| 2023-11-07 | 2023-09-30 | 0000950170-23-059769 | EDGAR | 22K words |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039394 | EDGAR | 21K words |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019166 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024685 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-015760 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-02 | 0001193125-26-380194 | EDGAR | 1K words |
| 2026-08-10 | 0001193125-26-341315 | EDGAR | 2K words |
| 2026-08-10 | 0001193125-26-342695 | EDGAR | 1K words |
| 2026-02-17 | 0001193125-26-053131 | EDGAR | 3K words |
| 2025-12-08 | 0001193125-25-311217 | EDGAR | 2K words |
| 2025-11-18 | 0001193125-25-286158 | EDGAR | 43K words |
| 2025-11-13 | 0001193125-25-278679 | EDGAR | 2K words |
| 2025-11-10 | 0001193125-25-273315 | EDGAR | 3K words |
| 2025-11-03 | 0001193125-25-261797 | EDGAR | 2K words |
| 2025-09-11 | 0001193125-25-201353 | EDGAR | 38K words |
160 total filings indexed. 130 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001622229 |
| Ticker | COGT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.cogentbio.com |
| Listed | 2018-03-29 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/COGT (~200 tokens, structured JSON with cryptographic provenance)